BAKER BROS. ADVISORS LP — MADRIGAL PHARMACEUTICALS INC MDGL: Quarterly 13F Position History
BAKER BROS. ADVISORS LP has reported MADRIGAL PHARMACEUTICALS INC (MDGL) on 39 13F-HR filings in Pactolio's tracked window, first appearing in Q3 2016. As of Q1 2026, the position is sized at 2,141,701 shares ($1.12B market value, 6.44% of the equity book).
- 2,141,701Shares Held (Latest Filing)
- $1.12BReported Market Value (Latest Filing)
- 6.44%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$126.1MQuarter-over-Quarter Value Change
- 2,141,701Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 39 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,141,701 | 0 | — | $1.12B | 6.44% | $523.47 |
| Q4 2025 | 2,141,701 | 0 | — | $1.25B | 7.30% | $582.34 |
| Q3 2025 | 2,141,701 | +165,683 | +8.4% | $982.3M | 7.10% | $458.66 |
| Q2 2025 | 1,976,018 | +1,428 | +0.1% | $598.0M | 5.80% | $302.64 |
| Q1 2025 | 1,974,590 | 0 | — | $654.0M | 7.24% | $331.23 |
| Q4 2024 | 1,974,590 | 0 | — | $609.3M | 6.51% | $308.57 |
| Q3 2024 | 1,974,590 | 0 | — | $419.0M | 4.34% | $212.22 |
| Q2 2024 | 1,974,590 | +4,792 | +0.2% | $553.2M | 7.07% | $280.16 |
| Q1 2024 | 1,969,798 | 0 | — | $526.0M | 6.60% | $267.04 |
| Q4 2023 | 1,969,798 | +424,685 | +27.5% | $455.8M | 5.19% | $231.38 |
| Q3 2023 | 1,545,113 | 0 | — | $225.6M | 1.30% | $146.04 |
| Q2 2023 | 1,545,113 | 0 | — | $356.9M | 2.07% | $231.00 |
| Q1 2023 | 1,545,113 | 0 | — | $374.3M | 2.04% | $242.26 |
| Q4 2022 | 1,545,113 | +45,900 | +3.1% | $448.5M | 2.69% | $290.25 |
| Q3 2022 | 1,499,213 | 0 | — | $97.4M | 0.64% | $64.99 |
| Q2 2022 | 1,499,213 | 0 | — | $107.3M | 0.61% | $71.58 |
| Q1 2022 | 1,499,213 | 0 | — | $147.1M | 0.85% | $98.12 |
| Q4 2021 | 1,499,213 | 0 | — | $127.0M | 0.62% | $84.74 |
| Q3 2021 | 1,499,213 | 0 | — | $119.6M | 0.53% | $79.79 |
| Q2 2021 | 1,499,213 | 0 | — | $146.0M | 0.64% | $97.41 |
| Q1 2021 | 1,499,213 | 0 | — | $175.4M | 0.76% | $116.97 |
| Q4 2020 | 1,499,213 | 0 | — | $166.7M | 0.63% | $111.17 |
| Q3 2020 | 1,499,213 | +1 | +0.0% | $178.0M | 0.71% | $118.73 |
| Q2 2020 | 1,499,212 | 0 | — | $169.8M | 0.75% | $113.25 |
| Q1 2020 | 1,499,212 | +329,934 | +28.2% | $100.1M | 0.62% | $66.76 |
| Q4 2019 | 1,169,278 | 0 | — | $106.5M | 0.57% | $91.11 |
| Q3 2019 | 1,169,278 | 0 | — | $100.8M | 0.69% | $86.22 |
| Q2 2019 | 1,169,278 | 0 | — | $122.6M | 0.83% | $104.81 |
| Q1 2019 | 1,169,278 | 0 | — | $146.5M | 0.94% | $125.26 |
| Q4 2018 | 1,169,278 | 0 | — | $131.8M | 1.08% | $112.72 |
| Q3 2018 | 1,169,278 | 0 | — | $250.4M | 1.65% | $214.13 |
| Q2 2018 | 1,169,278 | +553,594 | +89.9% | $327.0M | 2.46% | $279.69 |
| Q1 2018 | 615,684 | 0 | — | $71.9M | 0.61% | $116.79 |
| Q4 2017 | 615,684 | +557,922 | +965.9% | $56.5M | 0.49% | $91.79 |
| Q3 2017 | 57,762 | 0 | — | $2.6M | 0.02% | $44.98 |
| Q2 2017 | 57,762 | 0 | — | $939.0K | 0.01% | $16.26 |
| Q1 2017 | 57,762 | 0 | — | $890.0K | 0.01% | $15.41 |
| Q4 2016 | 57,762 | 0 | — | $861.0K | 0.01% | $14.91 |
| Q3 2016 | 57,762 | — | — | $732.0K | 0.01% | $12.67 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did BAKER BROS. ADVISORS LP first disclose a MDGL position in 13F-HR filings?
BAKER BROS. ADVISORS LP first reported MADRIGAL PHARMACEUTICALS INC (MDGL) on its 13F-HR filing for the period ending 2016-09-30 (Q3 2016). The position has appeared on 39 reported quarters within Pactolio's tracked window.
What was BAKER BROS. ADVISORS LP's most recent quarter-over-quarter share-count change in MDGL?
BAKER BROS. ADVISORS LP held the same 2,141,701 shares of MDGL between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent BAKER BROS. ADVISORS LP's cost basis in MDGL?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.